LDL-apheresis reduces P-selectin, CRP and fibrinogen - Possible important implications for improving atherosclerosis

Therapeutic Apheresis and Dialysis

Volumn 10, Issue 3, 2006, Pages 219-223

  Kobayashi, Shuzo ^a   Oka, Machiko ^a   Moriya, Hidekazkeu ^a   Maesato, Kyoko ^a   Okamoto, Koji ^a   Ohtake, Takayasu ^a  

^a SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

Author keywords

C reactive protein; Coronary artery stenosis; LDL apheresis; P selectin; Peripheral arterial occlusive disese (PAOD)

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; HEMODIALYSIS; HUMAN; LIMB ISCHEMIA; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL;

ADULT; AGED; ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; C-REACTIVE PROTEIN; CORONARY STENOSIS; FEMALE; FIBRINOGEN; HEMOPERFUSION; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; P-SELECTIN; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 33745572748     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2006.00332.x     Document Type: Article

References (37)

1. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
2. Yokoyama S, Hayashi R, Satani M et al. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 1985;5:613-21.
3. Saal SD, Parker TS, Gordon BR et al. Removal of low-density lipoproteins in patients by extracorporeal immunoadsorption. Am J Med 1986;80:583-9.
4. Thompson GR, Myant NB, Kilpatrick D et al. Assessment of long-term plasma-exchange for familial hypercholesteromia. Br Heart J 1980;43:680-90.
5. Rubba P, Postiglione A, Scarpato N et al. Improved reactive hyperemia test after plasma exchange in familial hypercholesteromia. Atherosclerosis 1985;56:237-42.
6. Agishi T, Kitano Y, Suzuki T et al. Improvement of peripheral circulation by low density lipoprotein adsorption. ASAIO Trans 1989;35:349-51.
7. Agishi T, Naganuma S, Nakasato S et al. Treatment of arteriosclerotic obstruction by LDL adsorption. Angiology 1993;44:222-7.
8. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001;106:148-56.
9. Zapf J, Froesch ER. Insulin-like growth factor/somatomedins: structures, secretion, biological actions and physiological role. Horm Res 1986;24:121-30.
10. Hansson H, Jennische E, Skottner A. Regenerating endothelial cells express insulin-like growth factor-I immunoreactivity after arterial injury. Cell Tissue Res 1987;250:499-505.
11. Kobayashi S, Moriya H, Ohtake T et al. LDL-apheresis up-regulates VEGF and IGF-I in patients with ischemic limb. J Clin Apher 2003;18:115-19.
12. Kroon AA, Aengevaeren WR, van der Werf T et al. The LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
13. Matsuzaki M, Hiramori K, Imaizumi T et al. Intravenous ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia. The low density lipoprotein-apheresis coronary morphology and reserve trial (LACMART). J Am Coll Cardiol 2002;40:220-7.
14. Mii S, Mori A, Sakata H et al. LDL-apheresis for arteriosclerosis obliterans with occluded bypass graft: change in prostacyclin and effect on ischemic syndrome. Angiology 1998;49:175-80.
15. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
16. Schachinger V, Zeiher AM. Atherosclerosis - recent insight into basic mechanisms and their clinical impact. Nephrol Dial Transplant 2002;17:2055-64.
17. Verma S, Buchanan MR, Anderson TJ. Endothelial function Testing as a biomarker of vascular disease. Circulation 2003;108:2054-9.
18. Burger PC, Wagner DD. Platelet P-selectin fascilitates atherosclerotic lesion development. Blood 2003;101:2661-6.
19. Blann AD, Lip GYH. Hypothesis: is Soluble P-selectin a new marker of platelet activation? Atherosclerosis 1997;128:135-8.
20. Kobayashi S. LDL-aphereis for diabetic nephropathy: a possible new tool. Nephron 1998;79:505-6.
21. Koenig W, Ditschuneit HH, Grunewald RW et al. Blood rheology after apheresis using dextran sulfate cellulose absorption - a case report. Angiology 1992;43:606-9.
22. Naganuma S, Agishi T, Ota K. Effect of LDL-aphereis on lipoprotein (a) levels in arteriosclerotic obliterans. Artif Organs 1991;15:336-9.
23. Murashima J, Ueki Y, Matsunaga Y et al. Removal of low-density lipoprotein from plasma by adsorption increases bradykinin and plasma nitric oxide levels in patients with peripheral atherosclerosis. Blood Coagul Fibrinolysis 1998;9:725-32.
24. Uno H, Ueki Y, Murashima J et al. Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerotic obliterans. Atherosclerosis 1995;116:93-102.
25. Tamai O, Matsuoka H, Itabe H et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82.
26. Kobayashi S, Moriya H, Maesato K et al. LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. J. Clin. Apher 2005;20:239-43.
27. Stenvinkel P, Heimburger O, Paultre F. Strong association between malnutrition, inflammation, and atherosclerosis in chronic kidney disease. Kidney Int 2000;55:1899-911.
28. Ridker PM, Hennekens CH, Buring JE. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
29. Hsu-Lin SC, Berman CL, Furie BC et al. A platelet membrane protein expressed during platelet activation and secretion. J Biol Chem 1984;259:9121.
30. Blann AD, Seigneur M, Boisseau MR et al. Soluble P-selectin in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease and its risk factos. Blood Coagul Fibrinolysis 1996;7:789-96.
31. Szmitko PE, Wang C, Weisel RD et al. Biomarkers of vascular disease linking inflammation to endothelial activation. Circulation 2003;108:2041-8.
32. Merril EW. Rheology of blood: the increase of viscosity correlating with increased fibrinogen levels in patients with intermittent claudication. Physiol Rev 1969;49:863-6.
33. Ward AS, Porter N, Preston FE. Platelet aggregation in patients with peripheral arterial disease. Atherosclerosis 1978;29:63-8.
34. Lowe GDO, Fowkes FGR, Dawes J et al. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993;87:1915.
35. Beer FC, Soutar AK, Baltz ML et al. Low density lipoprotein and very low density protein are selectively bound by aggregated C-reactive protein. J Exp Med 1982;156:230-242.
36. Kojima S, Shida M, Yokoyama H. Changes in C-reactive protein levels during low-density lipoprotein apheresis. Ther Apher Dial 2003;7:431-4.
37. Ohtake T, Kobayashi S, Moriya H et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005;16:1141-8.